neurodegenerative conditions
Secarna and Vect-Horus collaborate to advance therapies for central nervous system disorders
July 14, 2025Mergers and Acquisitions, Research and Development Neurology, Secarna Pharmaceuticals, Vect-Horus, central nervous system, neurodegenerative conditions
Secarna Pharmaceuticals and Vect-Horus have announced that the companies will collaborate to develop RNA-targeted therapeutics capable of crossing the blood-brain …
Galimedix completes key stage of clinical trial for treatment targeting eye and brain diseases
May 9, 2025Research and Development Galimedix Therapeutics, Neurology, Opthalmology, R&D, clinical trial, neurodegenerative conditions
Clinical biotech, Galimedix Therapeutics, has announced the completion of a single ascending dose (SAD) part of a phase 1 study …
Alchemab Therapeutics signs $415m licensing agreement for ALS programme with Eli Lilly
May 7, 2025Mergers and Acquisitions Alchemab Therapeutics, Corporate, Eli Lilly and Company, Immunology, M&A, als, immunology, neurodegenerative conditions
Alchemab Therapeutics, an immunotherapy-focused biopharma company, has entered a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, its …
Latest content
FibroFind appoints Lee Borthwick as CEO
July 21, 2026
